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Enterotoxigenic Escherichia coli (ETEC) is a major cause of childhood diarrhoea in the 
developing world and the most common cause of travellers’ diarrhoea. A new oral 
multivalent ETEC vaccine (MEV) containing killed recombinant E. coli bacteria 
expressing increased levels of the most prevalent ETEC colonisation factors (CFs), i.e. 
CFA/I, CS3, CS5 and CS6, and the toxoid LCTBA, a hybrid between the binding 
subunits of ETEC heat labile toxin (LTB) and cholera toxin (CTB), has been developed 
at the University of Gothenburg. The main aim of this thesis was to analyse immune 
responses induced by MEV and related vaccines in humans, and to evaluate different 
approaches to enhance and measure such responses. 
 The safety and immunogenicity of two oral doses of a prototype of MEV, 
containing CFA/I over-expressing E. coli bacteria and LCTBA, were evaluated in a 
Phase I trial in adult Swedish volunteers. The vaccine was safe and induced significant 
faecal secretory IgA and intestine-derived antibody-secreting cell (ASC) IgA responses 
in peripheral blood against CFA/I and LTB, as well as IL-17A and IFNγ T cell 
responses to LTB. However, detailed studies of the kinetics of ASC responses induced 
by an oral inactivated model vaccine, the CTB-containing cholera vaccine Dukoral®, 
indicated that peak ASC responses may have been missed in the prototype ETEC 
vaccine trial assessing ASC responses 7 days after each vaccine dose. Thus, whereas 
CTB-specific ASC responses to Dukoral® peaked around 9 days after the first dose, 
ASC responses to a second or late booster dose (given 6 months - 14 years later) peaked 
already on day 4-5. The distinct kinetics of ASC responses to primary and booster 
vaccinations suggests that early peak ASC responses may indicate the presence of 
mucosal B cell memory. 
 In preparation for testing MEV with the mucosal adjuvant double-mutant LT 
(dmLT), we evaluated the effect of dmLT on human T cell responses in vitro. dmLT 
enhanced both IL-17A and IFNγ responses to LTB in cells from ETEC vaccinees and 
IL-17A responses to mycobacterial antigens in cells from BCG vaccinees; this effect 
was dependent on IL-1β and IL-23, and could be mediated via monocytes. 
 We also studied the functional characteristics of the antibody responses induced by 
MEV. Two oral doses administered ± dmLT to adult Swedish volunteers, as well as a 
single booster dose administered 13-23 months later, induced cross-reactive mucosal 
antibody responses to multiple related, non-vaccine CFs. Using a novel assay, we 
showed that the avidity of both mucosal and serum antibodies to key vaccine antigens 
increased in response to the late booster dose.  
 Collectively, our results indicate that MEV can induce mucosal antibodies with the 
potential to protect against a broad range of ETEC strains. Our demonstration that 
dmLT can enhance T cell responses indicates that dmLT may promote B cell 
differentiation and memory development. Our studies of the kinetics of ASC responses 
have indicated optimal sampling time points for performing such analyses and 
established a method for memory assessment. These results are important for continued 
clinical evaluation of the new ETEC vaccine.  
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